论文部分内容阅读
刘利平博士接受本刊专访,解构君圣泰有关多肽药物的研发创新中国的多肽药物市场正面临尴尬境地。在医药领域,多肽药物主要用于治疗癌症、心血管疾病、免疫代谢类疾病、血液病、传染性疾病,同时对疼痛缓解、记忆力减退、精神失常也有显著疗效。近年来,随着中国心脑血管疾病、肿瘤、糖尿病等疾病的罹患率逐年上升,我国的多肽市场增长远快于全球,年复合增长率更是在20%以上。然而,在我国多肽药物市场的整体规模迅速扩大的同时,却面临着跨国药企巨头占据市场大部分份额、本
Interview with Dr. Liu Liping Interview Jun Shengtai R & D and Innovation on Peptide Drugs The market for peptide drugs in China is facing an awkward situation. In the field of medicine, peptide drugs are mainly used to treat cancer, cardiovascular diseases, immune and metabolic diseases, hematological diseases and infectious diseases, and also have remarkable curative effects on pain relief, memory loss and mental disorders. In recent years, with the increasing incidence of diseases such as cardiovascular and cerebrovascular diseases, tumors and diabetes in China, the polypeptide market in our country grows much faster than that in the world, and the compound annual growth rate is more than 20%. However, while the overall scale of the peptide drug market in our country is rapidly expanding, it is still facing a large share of the market for transnational pharmaceutical companies.